---
document_datetime: 2023-09-21 22:02:04
document_pages: 32
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ebilfumin-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ebilfumin-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 57.3159397
conversion_datetime: 2025-12-24 04:06:04.603934
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rebif

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3   | Summary   |
|----------------------|--------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IA/0156/G            | Thiswasanapplicationforagroupofvariations. | 30/05/2023                          |                                            | Annex II                        |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedfor all otherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics,annex II, labelling,package leaflet).The CD is issued within twomonths of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation(EU) No.712/2012, or within one yearfor other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | manufacturing sites                                                                                                                                                        |            |            |             |                                |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------|
| IAIN/0155           | B.IV.1.a.1-Change of a measuring or administration device-Addition orreplacement of adevicewhich is not an integrated part of the primary packaging - Devicewith CEmarking | 25/01/2023 |            | PL          |                                |
| IA/0154             | B.I.d.1.c-Stability of AS -Change in the re-test period/storage period or storage conditions - Change toan approvedstabilityprotocol                                       | 20/04/2022 | n/a        |             |                                |
| IA/0153             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                               | 17/02/2022 | n/a        |             |                                |
| PSUSA/10726 /202105 | PeriodicSafetyUpdateEUSingleassessment- interferonbeta-1a(subcutaneous use)                                                                                                | 13/01/2022 | n/a        |             | PRACRecommendation-maintenance |
| IA/0152             | B.I.a.2.z-Changes in the manufacturing process of theAS-Othervariation                                                                                                     | 10/09/2021 | n/a        |             |                                |
| IB/0150             | B.I.a.2.a-Changesin themanufacturingprocessof the AS-Minor changein themanufacturingprocess of the AS                                                                      | 04/05/2021 | n/a        |             |                                |
| IB/0149             | B.I.a.2.a-Changes in the manufacturing process of theAS-Minor changeinthemanufacturingprocess of the AS                                                                    | 18/12/2020 | n/a        |             |                                |
| IB/0148             | C.I.z-Changes(Safety/Efficacy)ofHuman and VeterinaryMedicinalProducts-Othervariation                                                                                       | 09/12/2020 | 13/12/2021 | SmPC and PL |                                |

<div style=\"page-break-after: always\"></div>

| IAIN/0147   | B.IV.1.a.1-Change of a measuring or administration device-Addition orreplacement of adevicewhichis not an integrated part of the primary packaging - DevicewithCEmarking                                                                                                    | 27/08/2020   | n/a        |             |                                                                                                                                                          |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0146   | B.IV.1.b -Change of a measuring or administration device-Deletionofadevice                                                                                                                                                                                                  | 21/08/2020   | 15/10/2020 | SmPC and PL |                                                                                                                                                          |
| IA/0145     | A.7-Administrativechange-Deletion of manufacturing sites                                                                                                                                                                                                                    | 15/07/2020   | n/a        |             |                                                                                                                                                          |
| I1/0144     | C.1.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of change(s)whichrequire tobefurthersubstantiated bynewadditionaldatatobesubmittedbytheMAH where significant assessment isrequired | 13/02/2020   | n/a        |             |                                                                                                                                                          |
| IB/0143     | C.I.3.a-Change(s) in the SPC,Labelling or PL intendedtoimplementtheoutcomeofaprocedure concerningPSURorPASSortheoutcomeofthe assessmentdoneunderA45/46-Implementationof wording agreedbythecompetent authority                                                              | 08/01/2020   | 15/10/2020 | SmPC and PL |                                                                                                                                                          |
| 11/0137/G   | This was an application for a group of variations. Toupdatesections4.3,4.6and5.3oftheSmPCin order toremove thecontraindication ontheinitiation of treatment in pregnancy and to update the recommendations on use in pregnancy and                                          | 19/09/2019   | 15/10/2020 | SmPC and PL | TheSmPCsection4.3hasbeenupdated toremovethe contraindication'initiation of treatmentinpregnancy'. TheSmPCsection 4.6hasbeen updated asfollows: Pregnancy |

<div style=\"page-break-after: always\"></div>

| breastfeedingfollowingthecompletionofthe EuropeanIFNBetaPregnancy Registry(8thAnnual and final report)and theFinal CSRof theregister- based study in the Nordic countries(EUPAS13054). TheMAHtooktheopportunitytoaddinformation abouttraceabilityinsection4.4andtoupdatethe ProductinformationtotheQRDtemplateversion 10.1. ThePackageleaflet hasbeen updated accordingly. This submission fulfils MEA 43.2 and 39. TheRMPhasbeenupdated(ver10.2) to include changestothesafetyspecificationrelatedto Pregnancymissinginformationstatus,inlightof the newsafety informationreceived,as well as updates tootherkeysectionsoftheRMP,adaptingtothe requirementsof theGVPModule5revision2 guidelines. C.I.4 -Change(s) in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data C.I.4 -Change(s) in the SPC,Labelling or PL due to new quality,preclinical, clinical or pharmacovigilance data   | A large amount of data (more than 1,0o0 pregnancy outcomes)fromregistriesandpost-marketingexperience indicatesnoincreasedriskofmajorcongenitalanomalies after pre-conception exposure to interferon beta or such exposure during the first trimester of pregnancy. However, the duration ofexposure during thefirsttrimester is uncertain,because data were collectedwhen interferon beta usewas contraindicated during pregnancy,and treatmentlikelyinterruptedwhenthepregnancywas detectedand/orconfirmed.Experiencewithexposure during the second and third trimester is very limited. Basedonanimaldata(seesection5.3),thereisapossibly increasedriskforspontaneous abortion.Therisk of spontaneousabortionsinpregnantwomenexposed to interferonbetacannotadequatelybeevaluatedbasedon thecurrently available data,but the data donotsuggest an increased risk sofar. If clinicallyneeded,theuse ofRebifmaybeconsidered during pregnancy. Breast-feeding Limited informationavailableon the transfer of interferon beta-1a intobreast milk,together with the chemical/physiologicalcharacteristicsofinterferonbeta, suggeststhatlevelsofinterferonbeta-1aexcreted in humanmilkarenegligible.Noharmfuleffectsonthe breastfednewborn/infant are anticipated.   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                   |            |     | TheSmPC section5.3hasbeen updated asfollows: A studyonembryo/foetal toxicityinmonkeysshowed no evidenceofreproductivedisturbances.Anincreasedriskof abortionshasbeenreportedinanimalstudiesofother alphaandbetainterferons.Noinformationisavailableon theeffectsof theinterferonbeta1aonmalefertility. The PL has been updated accordingly.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0141   | B.I.a.1.e-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS-The change relates to a biological AS or a starting material [-] used inthemanufactureof a biological/immunological product | 25/07/2019 | n/a |                                                                                                                                                                                                                                                                                                                                               |
| IA/0142   | B.II.b.5.a -Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                         | 09/07/2019 | n/a |                                                                                                                                                                                                                                                                                                                                               |
| IA/0140   | B.I.b.2.a-ChangeintestprocedureforASor startingmaterial/reagent/intermediate-Minor changesto anapprovedtestprocedure                                                                                              | 23/05/2019 | n/a |                                                                                                                                                                                                                                                                                                                                               |
| IA/0139   | B.II.d.2.a-Change in testprocedure for the finished product-Minorchangestoanapprovedtest procedure                                                                                                                | 08/05/2019 | n/a |                                                                                                                                                                                                                                                                                                                                               |
| IA/0138/G | Thiswas an applicationfor a groupof variations. B.II.e.2.a-Change in the specification parameters                                                                                                                 | 08/05/2019 | n/a |                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                    | and/orlimitsof theimmediatepackagingof the finished product -Tightening of specification limits B.II.e.3.a-Change in test procedure for the immediatepackagingof thefinishedproduct-Minor changes to an approved test procedure                                                                                                                                                                                                                |            |            |                        |                                |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| PSUSA/9198/ 201805 | PeriodicSafetyUpdateEUSingleassessment- interferonbeta-1a                                                                                                                                                                                                                                                                                                                                                                                      | 29/11/2018 | n/a        |                        | PRACRecommendation-maintenance |
| T/0135             | TransferofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                                                                               | 22/06/2018 | 13/07/2018 | SmPC, Labelling and PL |                                |
| IB/0134/G          | This was an application for a group of variations. B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.1.z-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation | 02/03/2018 | n/a        |                        |                                |
| IB/0133/G          | This was an applicationfor a group of variations. B.II.e.5.a.2-Change in pack size of thefinished product - Change in the number of units (e.g. tablets,ampoules,etc.）in a pack-Change outside the range of the currently approved pack sizes B.1I.e.5.a.2 - Change in pack size of the finished                                                                                                                                               | 19/12/2017 | 13/07/2018 | SmPC, Labelling and PL |                                |

<div style=\"page-break-after: always\"></div>

|         | product - Change in the number of units (e.g. tablets,ampoules,etc.)in a pack-Change outside therangeofthecurrentlyapprovedpacksizes                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                  |                   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|-------------------|
|         | B.I.a.2.a-Changes in the manufacturing process of the AS-Minor changein themanufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/12/2017 | n/a        |                  | IB/0132 of the AS |
|         | B.II.b.1.a-Replacementor addition of a manufacturingsitefortheFp-Secondarypackaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14/11/2017 | n/a        |                  | IAIN/0131 site    |
| I1/0129 | Submission of anupdatedRMPversion9.0 in order to upgrade the important potential risk \"Immunogenicity/safety risk associated with the formationof neutralizing antibodies\"to animportant identifiedrisk andrename it to \"Immunogenicity/formation ofneutralizing antibodies (NAbs) (reduced efficacy)\". C.I.11.b -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,includingtheRMP-Implementationof change(s)whichrequiretobefurthersubstantiated bynewadditionaldatatobesubmittedbytheMAH where significant assessmentisrequired | 06/07/2017 | n/a        |                  |                   |
| N/0130  | Minor change in labelling or package leaflet not connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 07/06/2017 | 13/07/2018 | Labelling and PL |                   |
| IB/0127 | B.I.a.2.z-Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21/02/2017 | n/a        |                  |                   |

<div style=\"page-break-after: always\"></div>

|         | the AS - Other variation                                                                                                                                                                                                                                                                                                                                       |            |     |                       |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|
| IA/0126 | B.II.e.6.b -Change in any part of the (primary) packaging material not in contact with the finished productformulation-Change thatdoesnot affect                                                                                                                                                                                                               | 30/11/2016 | n/a | theproductinformation |
| IA/0125 | B.I.d.1.c -Stability of AS -Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                       | 11/11/2016 | n/a |                       |
|         | B.II.e.7.a -Change in supplier of packaging components or devices(whenmentioned in the dossier)- Deletion of a supplier                                                                                                                                                                                                                                        | 27/10/2016 | n/a | IA/0124               |
| II/0122 | B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                                                                                                         | 15/09/2016 | n/a |                       |
|         | Thiswasanapplicationforagroupofvariations. A.4-Administrativechange-Change in thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturer of a novel excipient B.I.a.2.a-Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 19/05/2016 | n/a | IB/0121/G of the AS   |

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changestoan approved testprocedure                    |            |            |             |                                |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------|
| PSUSA/9198/ 201505 | PeriodicSafetyUpdateEUSingle assessment- interferon beta-1a                                                                                      | 03/12/2015 | n/a        |             | PRACRecommendation-maintenance |
| IB/0120            | C.1.11.z-Introduction of,or change(s) to, the obligations and conditions of a marketing authorisation,includingtheRMP-Othervariation             | 20/10/2015 | n/a        |             |                                |
| 11/0116            | C.I.13-Other variations not specifically covered elsewhereinthisAnnexwhichinvolvethesubmission of studies to the competent authority             | 17/09/2015 | n/a        |             |                                |
| IB/0119            | B.I.a.4.z-Change to in-process tests orlimits applied during the manufacture of the AS - Other variation                                         | 10/09/2015 | n/a        |             |                                |
| IB/0115            | C.I.z-Changes(Safety/Efficacy)ofHuman and VeterinaryMedicinalProducts-Othervariation                                                             | 10/07/2015 | 22/07/2016 | SmPC and PL |                                |
| IG/0500            | C.I.8.a-Introductionofor changesto a summary of Pharmacovigilance system-Changes inQPPV (includingcontactdetails)and/orchangesinthe PSMFlocation | 17/11/2014 | n/a        |             |                                |
| IB/0112            | B.I.a.4.b -Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits          | 10/11/2014 | n/a        |             |                                |

<div style=\"page-break-after: always\"></div>

| IA/0114/G   | This was an applicationfor a group of variations. B.II.e.7.b-Change in supplier of packaging componentsor devices(whenmentioned in the dossier)-Replacementoradditionofasupplier B.II.e.7.b - Change in supplier of packaging components ordevices(whenmentioned in the                                                                                                               | 07/11/2014   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0111     | B.II.b.4.f-Change in the batch size(including batch sizeranges)ofthefinishedproduct-Thescalefor a biological/immunologicalmedicinalproductis increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                    | 02/10/2014   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0109     | B.I.a.4.f-Change toin-processtestsorlimits appliedduring themanufactureof theAS-Addition orreplacementof anin-processtestasaresultofa safetyorqualityissue                                                                                                                                                                                                                            | 30/09/2014   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 11/0106     | Updateof theSmPCSections 4.4 and4.8toinclude classlabellingwording onthrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura(TTP)and haemolytic uraemic syndrome (HuS).ThePackage leaflethas been updated accordingly.In addition theRMPwas updated to version 7.0. C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation | 24/07/2014   | 26/08/2014 | SmPC and PL | TheMAHconductedacumulativesearchforcasesof thromboticmicroangiopathy.Further to thePRACreview of these data,the CHMPconcurredwith thePRAC'sviewthat theremightbeacausalrelationshipbetweentheclassof interferons and thromboticmicroangiopathy,and that the PI should beupdated accordingly.Furthermore,the CHMP concurred thatawarning abouttheriskof thrombotic microangiopathy,includingrecommendationsfor monitoring of early symptoms, prompt treatment and discontinuationofinterferonbetaproductswhenthe reaction occurs,shouldbe added to theProduct |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             | Information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0461 | C.I.8.a-Introduction of or changes to a summary of Pharmacovigilancesystem-ChangesinQPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                               | 22/07/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0107 | A.7-Administrative change-Deletion of manufacturingsites                                                                                                                                                                                                                                                                                                                                               | 04/07/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| I1/0105 | Updateofsection5.1oftheSummaryofProduct Characteristics(SmPC) in order to include informationaboutbiologicalresponsemarkers and section5.2inordertoupdatetheinformationabout thepharmacokineticproperties. Furthermore, the PI was brought in line with the latestQRD templateversion9.0. C.I.4 -Change(s) in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data | 25/04/2014 | 26/08/2014 | SmPC and PL | Further to theirreviewofresultsfrom theStudy EMR200136-027evaluatingpharmacokinetics, pharmacodynamics，safetyandtolerabilityofRebifin healthyvolunteers,theCHMPconcludedthatinformation aboutmarkersofbiologicalresponseshouldbeaddedto section5.1oftheSmPC andsection5.2of theSmPC shouldbeupdatedtoreflectonnewlyavailabledataon absorption, distribution and elimination.                                                                                                                                        |
| I1/0104 | Updateofsections4.4and4.8of theSummaryof ProductCharacteristics(SmPC)in order to add safety informationwithregards tonephroticsyndrome and glomerulosclerosis.ThePackageLeafletwasupdated in accordance. C.I.z-Changes(Safety/Efficacy)ofHuman and VeterinaryMedicinal Products-Other variation                                                                                                        | 25/04/2014 | 26/08/2014 | SmPC and PL | TheMAHconductedacumulativesearchforcasesof glomerulosclerosisandnephroticsyndrome.Further to their reviewofthesedata,theCHMPwas ofthe opinionthat theremightbeacausalrelationshipbetweeninterferon beta 1-a and glomerulosclerosis and nephrotic syndrome, and thatthePI shouldbe updated accordingly. Furthermore,theCHMPconcluded thatawarning aboutthe risk of nephrotic syndrome (including examples of underlying conditions)andarecommendation to periodically assess renal function were of relevance to the |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |            | prescriber andshouldbeadded to theSmPC.                           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------|-------------------------------------------------------------------|
| I1/0103   | Update ofsections4.2 and4.8of theSmPCinorder toaddsafetyinformationrelevantto thepaediatric population. The Package Leaflet was updated accordingly. C.I.4 -Change(s) in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data                                                                                                                                                                                                         | 18/12/2013 | 28/02/2014 | SmPC andPL | Pleaserefer to the scientificdiscussionRebif H-000136-II- 103-AR. |
| N/0102    | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                                                                                                                       | 09/10/2013 | 28/02/2014 | PL         |                                                                   |
| IA/0101   | B.II.e.7.a-Change in supplier of packaging components or devices (when mentioned in the dossier)-Deletion of asupplier                                                                                                                                                                                                                                                                                                                                                    | 21/08/2013 | n/a        |            |                                                                   |
| IB/0100/G | Thiswasanapplicationforagroupofvariations. B.I.a.2.a-Changesinthemanufacturingprocessof theAS-Minor change in themanufacturingprocess of the AS B.I.a.2.a-Changes in the manufacturing process of theAS-Minor changein themanufacturingprocess of theAS B.I.a.2.a-Changes in the manufacturingprocess of theAS-Minor changein themanufacturingprocess of the AS B.I.a.2.a -Changes in the manufacturing process of theAS-Minor changein themanufacturingprocess of the AS | 07/08/2013 | n/a        |            |                                                                   |

<div style=\"page-break-after: always\"></div>

|         | B.I.a.2.a - Changes in the manufacturing process of theAS-Minor changein themanufacturingprocess                                                                                                                                                                                                                                             |            |     | of the AS   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| IB/0098 | B.II1.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new tests and limits                                                                                                                                                                                               | 23/07/2013 | n/a |             |
|         | B.IV.1.a.1-Change of a measuring or administration device-Additionorreplacementof adevicewhichis notanintegratedpartof theprimarypackaging- Device with CE marking                                                                                                                                                                           | 16/07/2013 | n/a | IAIN/0099   |
| IB/0097 | B.II.b.5.b-Change to in-process tests or limits appliedduring themanufactureofthefinished product - Addition of a new tests and limits                                                                                                                                                                                                       | 21/06/2013 | n/a |             |
| IB/0096 | B.I.a.4.b -Change to in-process tests or limits applied during the manufacture of the AS - Addition of a newin-process test andlimits                                                                                                                                                                                                        | 18/06/2013 | n/a |             |
|         | Thiswasanapplicationforagroupofvariations. Toreplace theaQCanalytical methodfordrug substance anddrugproduct and toamend correspondingspecifications B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement)toabiological/immunological/ immunochemical test method or a method using a | 30/05/2013 | n/a | II/0094/G   |

<div style=\"page-break-after: always\"></div>

|           | biologicalreagentfor abiologicalAS B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.II.d.1.z-Change in the specification parameters and/orlimitsofthefinishedproduct-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0095 | B.I.a.1.a-Change in themanufacturer ofASor of a startingmaterial/reagent/intermediateforAS-The proposedmanufacturerispartofthesame pharmaceuticalgroupasthecurrentlyapproved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/02/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0093   | Updateofsection4.8oftheSmPCinordertoadd \"pancytopenia\" and \"increased sweating\" as adverse reactions,following apreviousPSuRassessment.In addition, frequency categories of adverse reactions in section4.8oftheSmPCwerere-calculatedbasedon theSmPCguideline.ThePackageLeafletwas updated accordingly. Furthermore, the MAH proposed this opportunity to bring thePI inlinewith the latestQRDtemplate version8.3andtointroduceminoreditorialchanges. C.I.3.b-Implementationofchange(s)requested following theassessmentofanUSR,classlabelling,a PSUR,RMP,FUM/SO,datasubmittedunderArticle 45/46,or amendmentstoreflectaCoreSPC- Change(s)with new additional data submitted by the MAH | 21/02/2013 | 28/02/2014 | SmPC, Annex II, Labelling and PL | Following conclusions ofa previousPSuRassessment,the MAHcompliedwiththerequestoftheCHMPtoupdatethe ProductInformationbyaddingtheadversereactions \"pancytopenia\"and\"increasedsweating\". Withrespecttopancytopenia,theCHMPconsideredthe availableliteraturedataconcerningtheeffectsofinterferon onbloodcells and the availableclinical datafrom clinical trials andpost-marketing setting.The CHMPconsidered thatnoserious casesofpancytopeniawereobserved in clinical trial andnoreports concerningpancytopenia were identifiedinliterature，butcasesofpancytopeniawere reported in the post-marketing setting. Taken together with theknowneffectofIFNonbloodcells,thepossibilityof decreaseinseveralbonemarrowcell-linesandanumberof cases ofpositive de-challenge and even a couple of cases withpositivere-challenge,the evidence available was considered supportive of at least a possible causality. Thus, theCHMPconcludedon theneed toupdatesection4.8of |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                      |            |            |             | theSmPCbyincludingpancytopenia as anadverse reaction. Thelevel ofevidence availablewiththepreviousPSuRwas sufficienttosupportaddingincreasedsweatingtothePI without a needfor additional data. TheCHMPendorsed theMAH'sfrequencyestimationsof both pancytopenia and excessive sweating and considered that these substantiated the frequency category\"rare\" for pancytopenia and \"uncommon\" for excessive sweating. TheCHMPalsoacknowledgedthattheMAHfollowedthe SmPCguidelineandestimatedfrequenciesforalladverse reactions previously categorised asfrequency\"notknown\". TheCHMPendorsedtheMAH'sproposalsforthenew frequency categories and agreed on the update of section 4.8 of theSmPC.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0224 | C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Other variation                                                                                                                                                                                                                                                                               | 11/10/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 11/0091 | Updateofsection4.8oftheSmPCinordertoadd thefollowingadversereactionsidentifiedduringthe post-marketing surveillance:autoimmunehepatitis and drug-induced lupus erythematosus. The Package Leaflet was updated in accordance. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdue inparticular tonewquality,pre- clinical,clinical orpharmacovigilancedata | 24/05/2012 | 27/06/2012 | SmPC and PL | ThisupdateofProductInformationfollowedacumulative reviewofcasesofautoimmunehepatitisandsystemic lupuserythematosusinmultiplesclerosispatientsexposed tointerferon-beta-1a.Itwasbased onthe company's internalsafetydatabase,pooledclinicaltrialdatabase，the FDAadverse eventreporting system(AERS)database,as wellason aliterature review.The CHMPconsidered that thelevelofevidenceavailablethroughsafetyreporting allowedestablishingacausalrelationshipwithautoimmune hepatitisanddrug-inducedlupuserythematosusandthatit indicatedincreasedriskofoccurrenceofthesereactionsin multiplesclerosispatientstreatedwithRebif.                                                                    |

<div style=\"page-break-after: always\"></div>

| I1/0088/G   | Thiswasanapplicationforagroupofvariations.                                                                                                                                   | 17/11/2011   | 20/01/2012   | SmPC, Annex II, Labelling   | PleaserefertothescientificdiscussionRebifH-136-II-88G- AR   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------------|-------------------------------------------------------------|
| IAIN/0089   | B.IV.1.a.1-Change of a measuring or administration device-Addition orreplacement of adevicewhich is not an integrated part of the primary packaging - Device with CE marking | 18/11/2011   | n/a          |                             |                                                             |

<div style=\"page-break-after: always\"></div>

|           | B.IV.1.a.1-Change of a measuring or administration device-Addition orreplacement of a devicewhich is notanintegratedpartof theprimarypackaging-                                                                                                                                                                                                                                                                                                                | 08/08/2011   | n/a        | SmPC, Annex II, Labelling and PL   | IB/0087 Device with CEmarking   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------------------|---------------------------------|
| IG/0076/G | This was an application for a group of variations. C.I.9.a-Changes to an existingpharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b-Changes to anexisting pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h-Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system | 01/07/2011   | n/a        |                                    |                                 |
|           | Minorchangeinlabellingorpackageleafletnot connectedwith theSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                                                                                                           | 04/05/2011   | n/a        | Labelling and PL                   | N/0086                          |
|           | Thiswas an applicationfor a group of variations. -Tochangetheactivesubstanceandfinishedproduct specifications. -Tochange the shelf-life of the active substance. B.I.b.1.f -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Changeoutsidethe approved specifications limitsrangefor the AS                                                                                                               | 17/02/2011   | 25/02/2011 |                                    | I1/0085/G                       |

<div style=\"page-break-after: always\"></div>

|           | B.I.d.1.a.1-Stability of AS -Change in the re-test period/storage period - Reduction B.II.d.1.e -Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                             |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0084/G | Thiswas an applicationfor a group of variations. B.II.e.5.a.2-Change in pack size of the finished product - Change in the number of units (e.g. tablets,ampoules,etc.）in a pack-Change outside therangeofthecurrentlyapprovedpacksizes B.II.e.5.a.2-Change in pack size of the finished product - Change in the number of units (e.g. tablets,ampoules,etc.）in a pack-Change outside the range of the currently approved pack sizes | 09/09/2010 | 09/09/2010 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 11/0081   | UpdateoftheSummaryofProductCharacteristics (Section 4.8)andPackage Leaflet(Section 4). UpdateofSummaryofProductCharacteristicsand PackageLeaflet                                                                                                                                                                                                                                                                                    | 24/06/2010 | 06/08/2010 | SmPC and PL            | The product information was updated to include \"hepatic failure\"insection4.8of theSmPCandtoaddinformation on symptoms of severe liver problems in Section 4 of the PackageLeaflet.The update wasbased on a CHMP requirementfollowingassessmentofthePSuRs19and20 andwasfurthersupportedbyasummaryofavailable safety datapresentedby theMAH. Inaddition,theMAHtooktheopportunitytoreviewthe SOCorderwithinthetableinsection4.8oftheSmPCtobe compliantwith theorderdefinedintheSmPCguidelineand preferred term (PT) and includes \"hair loss\". |

<div style=\"page-break-after: always\"></div>

| I1/0082   | Additional manufacturer of activesubstance.                                                                                                | 22/04/2010   | 02/06/2010   | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0080   | Introductionof apre-filledpen as a newpresentation in additionto thecurrently approvedpre-filled syringe andcartridge. New presentation(s) | 22/04/2010   | 02/06/2010   | SmPC, Labelling and PL | TheproposedRebif pre-filledpen ismanufactured by inserting thecurrently approvedsyringes(8.8,22and44 micrograms)into a singleuse auto-injector,calledpre-filled pen.There are no changes in the drug substance or drug product (formulation, strength and primary container) of the currently approvedRebifpre-filled syringe.The only change is the additional step in the manufacturing process to assemble the pre-filled syringe into the pre-filled pen. Thepre-filledpen isfor singleuse i.e.injection of one dose ofRebif.Therearenochangesin the therapeutic indication,posology,administrationroute and treatment duration. |
| II/0079   | UpdateoftheDetailedDescriptionofthe Pharmacovigilancesystem(DDPS). UpdateofDDPS(Pharmacovigilance)                                         | 22/04/2010   | 02/06/2010   | Annex II               | WiththisvariationtheMAHsubmittedanewversionofthe DDPS(version9.0)inaccordancewiththecurrent Pharmacovigilanceguideline.After assessingthe documentation theCHMPconcluded thatthesubmitted DDPS contained all required elements. Consequently, AnnexIIhasbeenupdatedwiththenewversionnumber of                                                                                                                                                                                                                                                                                                                                        |
| N/0083    | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                        | 31/03/2010   | n/a          | Labelling and PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | Removal of a test from drug substance quality controlrelease specifications and tests Change(s)to the testmethod(s)and/or specifications for the active substance   | 21/01/2010   | 02/02/2010   |                         | 11/0078                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|-------------------------|
|         | Introductionof anewcellbankingsystemfor interferonbeta-1a Change(s)to themanufacturingprocessforthe                                                                 | 21/01/2010   | 02/02/2010   |                         | 11/0077 activesubstance |
|         | Revisionofthestorageconditions Change(s) to shelf-life or storage conditions                                                                                        | 24/09/2009   | 23/10/2009   | SmPC,  Labelling and PL | II/0074                 |
|         | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                 | 10/09/2009   | n/a          | PL                      | N/0076                  |
|         | Minor change inlabelling orpackageleaflet not connectedwiththeSPC(Art.61.3Notification)                                                                             | 28/07/2009   | n/a          | Labelling               | N/0073                  |
|         | IA_01_Change in thename and/or address of the marketing authorisationholder                                                                                         | 24/07/2009   | n/a          | SmPC, Labelling and PL  | IA/0075                 |
| I1/0072 | Changein thestorageconditions Updateofor change(s)tothepharmaceutical                                                                                               | 29/05/2009   | 01/07/2009   | SmPC, Labelling and PL  | documentation           |

<div style=\"page-break-after: always\"></div>

| II/0070   | Updateofsection4.8oftheSPCandsection4ofthe PL,in line with the CHMPconclusions on thePSUR (covering theperiodfrom 04.05.07to 03.05.08),the companycoresafetyinformationandQRD guidelines. UpdateofSummaryofProductCharacteristicsand PackageLeaflet   | 19/03/2009   | 22/04/2009   | SmPC and PL            | TheMAHconductedcumulativereviewsof thesafety informationavailableregarding theriskofmultiplesclerosis pseudo-relapses,retinalvascular disorder,thrombotic thrombocytopenic purpura and haemolytic uremic syndrome,inpatients treated withRebif.Thisresulted in theinclusionofthesesyndromesanddisordersaspossible adversedrugreactionsassociatedwithRebiftreatment. Thefrequencyforsuchadversedrugreactionscouldnotbe establishedbasedontheinformationavailable.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0071   | IA_O4_Changeinnameand/oraddressofamanuf. of the active substance (no Ph.Eur.cert.avail.) IA_05_Change in thename and/or addressof a manufacturerof thefinishedproduct                                                                                 | 10/03/2009   | n/a          | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| I1/0069   | Changeinthemanufacturingprocessoftheactive substance. Change(s)to the manufacturingprocessforthe activesubstance                                                                                                                                      | 22/01/2009   | 28/01/2009   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0067   | TheMAH applied to implement a new testmethod andrevised drug substance and drugproduct specifications. Change(s)to the testmethod(s)and/or specificationsforthefinishedproduct                                                                        | 22/01/2009   | 28/01/2009   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| X/0064    | Theapplicanthas appliedfor three additional presentations ofRebif: 8.8mcg/0.1ml, 22mcg/0.25ml(in a cartridge                                                                                                                                          | 20/11/2008   | 16/01/2009   | SmPC, Labelling and PL | The Marketing Authorisation Holder applied for the introduction of three additionalpresentationsofRebif: 8.8 mcg/0.1ml, 22 mcg/0.25ml (in a cartridge containing                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|         | containing1,5ml,correspondingto6dosesof8.8 mcg/0.1ml and 22 mcg/0.25ml,respectively) 44mcg/ml (in a cartridge containing 1.5ml, correspondingto3dosesof22mcg/0.5ml)and 88mcg/ml (in a cartridge containing 1.5ml, corresponding to 3 doses of 44 mcg/0.5 ml). Annex I_2.(d) Change or addition of a new pharmaceuticalform   |            |            |                 | 1,5ml,corresponding to 6 doses of 8.8 mcg/0.1ml and 22 mcg/0.25ml,respectively) 44 mcg/ml (in a cartridge containing 1.5ml, corresponding to 3 doses of 22 mcg/0.5 ml) and 88 mcg/ml (in a cartridge containing 1.5ml, corresponding to3 doses of44 mcg/0.5 ml). Thepresentations are solutionsforinjection in multidose pre-filled cartridges, which will allow the patient to administer the three weekly dosesform the same cartridge. Theexcipientsusedinthemanufactureof the approved and theproposedRebifHSA-freeformulations areidentical. ThemanufacturingprocessoftheproposedRebifdrug productincartridgesremains thesame as the manufacturing process of the approved Rebif in pre-filled syringes. There are no changes in the currently approved clinicalindication,route of administration,dosageregimen   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0065 | Change(s) to the drug product specifications. Change(s)tothetestmethod(s)and/or specifications for the finished product                                                                                                                                                                                                      | 23/10/2008 | 03/11/2008 |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0068 | IA_05_Change in the name and/or address of a manufacturerof thefinishedproduct                                                                                                                                                                                                                                               | 20/10/2008 | n/a        | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0063 | IA_05_Change in the name and/or address of a manufacturerofthefinishedproduct                                                                                                                                                                                                                                                | 05/06/2008 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IA/0062   | IA_16_b_SubmissionofnewTSEcertificaterelating toactive substance-othersubstances                                                                                                                    | 28/05/2008   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0061    | Renewalofthemarketing authorisation.                                                                                                                                                                | 19/03/2008   | 20/05/2008 | SmPC and PL                      | Basedontheirreviewoftheavailableinformation andon thebasisofare-evaluationofthebenefit/riskbalance,the CHMPwasof the opinion that the quality,safety and efficacy continue to be adequately and sufficiently demonstrated.Therefore,thebenefit/riskprofileofRebif continuestobefavourable.However,thereviewofsafety dataled to theinclusion of\"dyspnoea\"and\"Stevens- Johnsonsyndrome\"insection4.8oftheSPC.TheMAHwill continuetosubmityearlyperiodicsafetyupdatereports untilotherwisespecifiedbytheCHMP.TheCHMP recommended therenewaloftheMarketingAuthorisation for Rebif with unlimited validity. |
| I1/0060   | Updateofsection4.8oftheSummaryofProducts Characteristics(SPC)toreflect the overall percentageoftreatedpatientsexpected to experienceinjectionsitereactions. UpdateofSummaryofProductCharacteristics | 15/11/2007   | 14/12/2007 | SmPC                             | The48-weekresultsofstudy25632submittedforthe approval of the HSA-free formulation of Rebif showed an incidence rate of injection site reactions following administration of 44 mcg subcutaneously, three times per week,of29.6%in260subjects.Thisrepresentsalower incidenceratethanthe80to90%observedinthe historicalcomparatorstudiesor\"Historicalcohort,\"which comprised727subjects treatedwiththepreviousHSA- containing formulation of Rebif at 44 mcg subcutaneously three timesper week in three controlledstudies.                                                                            |
| II/0054   | Change in formulation                                                                                                                                                                               | 21/06/2007   | 10/08/2007 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| I1/0055   | Change(s)to the manufacturingprocessforthe activesubstance                                                                                                                                          | 21/06/2007   | 27/06/2007 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| II/0059   | Updateofsection4.2oftheSPCtoinclude information regarding the use of Rebif in paediatrics, asrecommendedby theCHMP.ThePackageLeaflet was amended accordingly.In addition theMAH took the opportunity to updatethe contactdetailsfor Spain,Portugal,France,Greece andSweden and to addlocalrepresentativesforthetwonewEUMember StatesBulgaria andRomania.AnnexII is amended accordingtothelatestQRDtemplate. UpdateofSummaryofProductCharacteristicsand PackageLeaflet   | 22/02/2007   | 28/04/2007   | SmPC, Annex II and PL   | Nospecificstudiesordatacollectionhavebeenconducted sofarbytheMAHinthepaediatricmultiplesclerosis population. The CHMP has reviewed published data on the useofinterferonbetainpaediatricpatients,mostlyinthe range of12to16yearsof age.In addition,the CHMP reviewed a recentpublicationprovided by the MAH and reporting the results of a 6-year open-label, prospective single-centrestudyassessing thesafety andtolerabilityof Rebifadministeredatdifferentdosesin24childrenor adolescent, including 8 children less than 10 years of age (TenembaumSN,SeguraM).Neurology2006;67:511- 513).Theinformation available onefficacy and safetyof interferonbetain childrenislimited.Efficacy cannot be consideredspecificallydemonstrated inchildrenbutthere arenosignalsofspecificsafetyissuesinpaediatric patients.Although thedata arescarce,theCHMP recommendedthattheavailableinformationisreflected in theproduct informationof all interferonbeta.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0058   | Change(s)to themanufacturingprocessforthe activesubstance Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                                                                                                                                                               | 16/11/2006   | 27/11/2006   |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| I1/0057   | ThisvariationrelatestotheupdateofSPCsections 4.3,4.4and4.6inordertoimplementtheinterferon beta class review SPC wording on contraindications adoptedby the CHMPinApril 2006.ThePackage Leaflethasbeen amended accordingly. UpdateofSummaryofProductCharacteristicsand                                                                                                                                                                                                   | 27/07/2006   | 01/09/2006   | SmPC and PL             | Further to therequestoftheCHMP,the CHMP PharmacovigilanceWorkingParty(PhvwP)performeda classreviewofallinterferonsbetaauthorisedinthe treatmentofmultiplesclerosistoproviderecommendations ontheneedfor and thenatureofchangesto thecurrent contraindications in pregnancy,patients with a history of severedepressivedisordersand/orsuicidalideationand                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Package Leaflet   | patientswithepilepsynot adequatelycontrolledby treatment.Basedon the data submittedby theMAH (clinical trial, post-marketing data and literature) and the   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| I1/0056   | TheMarketingAuthorisationHolder appliedfor an updateoftheSummaryofProductCharacteristics (sections 4.4,4.8 and 4.9)based on literature and post-marketingdata.ThePackageLeaflethasbeen updated accordingly. UpdateofSummaryofProductCharacteristicsand Package Leaflet   | 27/07/2006   | 01/09/2006   | SmPC and PL   | ThesafetyinformationoftheSPCwasupdatedbasedon literature and post-marketing data provided by the MAH. Therecommendationsforthemonitoringofhaematological laboratory parameters were amended in section 4.4 to providemoreinformationonthetimingofbloodcell counts.Section4.8wasupdated asfollows: Changeoffrequencyoftheadversereactions neutropenia，lymphopenia，leucopenia,thrombocytopenia andanemiafrom'Common'to'Very common\" Addition of \"injection site infections, including cellulitis\" Updateoftheendocrinedisordersrelated informationwiththereplacementofthewording\"elevated T3 and T4,reduced TSH\"by\"most often presenting as hypothyroidismorhyperthyroidism\" Section4.9was alsoupdatedfurther to thefirstreport of overdose withRebif.ThePackage Leafletwas updated in   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0053    | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                      | 31/05/2006   | n/a          | Labelling     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0052   | Thisvariationrelatestotheupdateof thewordingof section4.1 and5.1 in order to align themwith the current medical practice,taking into account the McDonaldcriteriaforthediagnosisofmultiple sclerosis. UpdateofSummaryofProductCharacteristics                            | 27/04/2006   | 31/05/2006   | SmPC          | The current indication of Rebif in the \"treatment of patients withmultiplesclerosisandwith2ormorerelapseswithin thelast2years\"reflectstheinclusioncriteriausedinthe clinicalstudieswhichformed thebasisfor approvalof Rebif,inlinewiththethenapplicablePoserdiagnostic criteriaofdefinitemultiplesclerosis.Asitstands，this indicationexcludesthepatientswithadiagnosisofMSwho havehad aclinicallyisolatedsyndromewithlesion disseminationonsubsequentMRIscans accordingtothe morerecentMcDonald'scriteria.Therefore,theindication                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        |                                                                                                                                                                                                                                                                 |            |            |                                  | wasrevisedso itis expressed in a wayas to align it with the current medicalpractice,whilekeeping it restricted to patients with diagnosed MS.The indication wording clarifies thatin clinical trialswhereRebifhasbeen administered,the diseasewascharacterisedbytwoormoreacute exacerbationsintheprevioustwoyears.Across-reference is made in section 4.1 tosection5.1 where the inclusion criteria used in the clinical trials supporting the original approval of Rebif (i.e. multiple sclerosis characterised by 2 or more acute exacerbations in the previous 2 years and with anEDSSof0-5.0 atentry)havebeenspecified.                                                                                                                                                                                                      |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0051 | TheMarketingAuthorisationHolder applied to introduceanewstrengthproductthatwillbe provided in a Initiation pack, containing 6 syringes of the8.8microgramsand22micrograms presentation,respectively. Annex I_2.(c) Change or addition of a new strength/potency | 15/09/2005 | 19/01/2006 | SmPC, Annex II, Labelling and PL | Currently,theregisteredstrengthsofRebifare22μgand 44μgin0.5ml.TherecommendedposologyofRebifis44 microgramsgiventhreetimesweeklybysubcutaneous injection.ThecurrentlyapprovedSPCalsoindicatesthat: \"When first starting treatment with Rebif, in order to allow tachyphylaxis todevelop thusreducing adversereactions,it isrecommendedthat8.8micrograms(0.1mlofthe44 microgramsstrengthor0.2mlofthe22micrograms strength)be administered during theinitial 2weeks of therapy,22micrograms(0.25mlofthe44micrograms strengthorthetotalofthe22microgramsstrength)be administeredinweeks3and4,andthetotalofthe44 microgramsstrengthbeadministeredfromthefifthweek onwards.\" An additionalstrength(Rebif8.8μg/0.2ml）willallowthe patienttofollowtherecommendedinitialdosetitration without theneed todiscardpart of thesyringecontent. |

<div style=\"page-break-after: always\"></div>

|         |                                                                                       |            |            |             | The new strength product will be provided in a \"Initiation pack\", containing 6 syringes of the 8.8 μg and 22 μg presentation, respectively. Each pre-filled syringe (1ml) is designed todeliver 0.2ml(for8.8μg)or0.5ml(for22μg) of a sterile,clear aqueoussolution.Theinterferon-B-1a8.8 ug finished product batches have been manufactured using the same compounding, manufacturing process, equipment and quality control procedures as for the currently marketed Interferon-B-1a finished product (22 and 44 μg) and are differing only in the syringe fill volume (0.2 ml instead of 0.5 ml per syringe).   |
|---------|---------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0050  | Minor changeinlabellingorpackageleafletnot connectedwith theSPC(Art.61.3Notification) | 19/11/2004 | n/a        | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0047 | Change(s) to the manufacturing process for the activesubstance                        | 23/06/2004 | 20/07/2004 | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0049 | Update of Summary of Product Characteristics and Package Leaflet                      | 17/12/2003 | 23/02/2004 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1/0046  | 15a_ChangeinIPCs applied during the manufacture of the product                        | 01/12/2003 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1/0045  | IA_07_a_Replacement/add.of manufacturing site: Secondary packaging site               | 01/12/2003 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| I1/0044 | Change(s)to the testmethod(s)and/or specificationsfortheactivesubstance               | 22/10/2003 | 30/10/2003 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1/0048  | 15a_ChangeinIPCsapplied during themanufacture of the product                          | 20/10/2003 | 22/10/2003 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| 1/0043   | 31_Change in container shape                                                                        | 20/08/2003   | 18/09/2003   |                        |                 |
|----------|-----------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------|
| 11/0038  | UpdateofSummaryofProductCharacteristicsand                                                          | 19/03/2003   | 25/06/2003   | SmPC and PL            | Package Leaflet |
| R/0040   | Renewalof themarketing authorisation.                                                               | 19/03/2003   | 04/06/2003   | SmPC, Labelling and PL |                 |
|          | Change(s)to the test method(s)and/or specificationsfortheactivesubstance                            | 22/05/2003   | 27/05/2003   |                        | II/0042         |
|          | Minor change in labelling or package leaflet not connected with the SPC(Art.61.3 Notification)      | 27/01/2003   | 04/03/2003   | PL                     | N/0039          |
|          | X-1-vi_Repl.of biological substance with one of a diff.molecular structure;modificationofvector     | 17/10/2002   | 16/01/2003   | Annex II               | X/0022          |
| 1/0037   | 12a_Change in specification of starting material/intermediate used in manuf.of the active substance | 11/12/2002   | 13/12/2002   |                        |                 |
| 1/0036   | 12_Minorchangeof manufacturingprocessof the activesubstance                                         | 22/08/2002   | 10/09/2002   |                        |                 |
|          | 11b_Change in supplier of an intermediate compoundused inmanufactureof the active substance         | 22/08/2002   | 10/09/2002   |                        | 1/0035          |
|          | Change(s)to the testmethod(s)and/or specificationsfor thefinished product                           | 25/07/2002   | 31/07/2002   |                        | I1/0033         |

<div style=\"page-break-after: always\"></div>

| 1/0034   | 24_Change in testprocedure of active substance 25_Change in test procedures of the medicinal   | 25/07/2002   | 31/07/2002   |                        | product          |
|----------|------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|------------------|
|          | Update of Summary of Product Characteristics and Package Leaflet                               | 21/02/2002   | 17/05/2002   | SmPC and PL            | I1/0030          |
|          | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)            | 11/03/2002   | 02/04/2002   | Labelling              | N/0032           |
| 1/0031   | 16_Change in the batch size of finished product                                                | 01/02/2002   | 11/02/2002   |                        |                  |
|          | Change(s)to the manufacturingprocessfor the active substance                                   | 15/11/2001   | 28/11/2001   |                        | II/0029          |
|          | Change(s)to the testmethod(s)and/or specifications for the active substance                    | 21/09/2000   | 20/11/2001   |                        | I1/0017          |
| 11/0011  | UpdateofSummaryofProductCharacteristicsand Package Leaflet                                     | 26/07/2001   | 20/11/2001   | SmPC and PL            |                  |
| 1/0028   | 20a_Extensionof shelf-lifeorretestperiodof the                                                 | 21/09/2001   | n/a          |                        | active substance |
|          | 03_Change in the name and/or address of the marketing authorisationholder                      | 26/07/2001   | 18/09/2001   | SmPC, Labelling and PL | 1/0026           |
| 1/0027   | 01_Changefollowingmodification(s)of the manufacturing authorisation(s)                         | 17/08/2001   | 07/09/2001   |                        |                  |

<div style=\"page-break-after: always\"></div>

|        | Minorchangeinlabellingorpackageleafletnot connected with the SPC(Art.61.3 Notification)   | 21/08/2001   | 03/10/2001   | Labelling   | N/0024           |
|--------|-------------------------------------------------------------------------------------------|--------------|--------------|-------------|------------------|
|        | 11b_Change insupplierof anintermediate compoundused inmanufactureof the active            | 09/08/2001   | n/a          |             | 1/0025 substance |
|        | 23_Change in storage conditions                                                           | 11/06/2001   | 19/07/2001   | SmPC and PL | 1/0021           |
|        | 11_Change in or addition of manufacturer(s) of activesubstance                            | 14/12/2000   | 20/03/2001   | Annex II    | 1/0015           |
| 1/0020 | 26_Changes to comply with supplements to pharmacopoeias                                   | 28/02/2001   | 11/03/2001   |             |                  |
|        | UpdateofSummaryofProductCharacteristics and PackageLeaflet                                | 19/10/2000   | 22/01/2001   | SmPC and PL | 11/0013          |
|        | 01_Changefollowingmodification(s)ofthe manufacturing authorisation(s)                     | 14/12/2000   | 20/12/2000   |             | 1/0019           |
|        | Annual re-assessment.                                                                     | 26/07/2000   | 08/12/2000   | Annex II    | S/0014           |
| 1/0016 | 12_Minor change of manufacturing process of the activesubstance                           | 21/09/2000   | n/a          |             |                  |
|        | 17_Change in specification of the medicinal product 31_Change incontainershape            | 01/09/2000   | n/a          |             | 1/0018           |
|        | 11b_Changeinsupplierofanintermediate compoundusedinmanufactureoftheactive                 | 16/03/2000   | n/a          |             | 1/0012           |

<div style=\"page-break-after: always\"></div>

|         | substance                                                                                    |            |            |                                  |                 |
|---------|----------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------|
| 1/0010  | 01_Change following modification(s)of the manufacturing authorisation(s)                     | 12/11/1999 | 20/01/2000 | Annex II and PL                  |                 |
| 1/0008  | 20_Extensionofshelf-lifeasforeseenattimeof                                                   | 05/10/1999 | 14/12/1999 | SmPC, Labelling and PL           | authorisation   |
| S/0003  | Annualre-assessment.                                                                         | 23/06/1999 | 03/12/1999 | Annex II                         |                 |
| 11/0009 |                                                                                              | 18/11/1999 | 02/12/1999 |                                  | Quality changes |
| N/0007  | Minor change in labelling or package leaflet not connectedwith theSPC(Art.61.3 Notification) | 07/10/1999 | 14/12/1999 | PL                               |                 |
| 1/0006  | 12_Minor change of manufacturing process of the activesubstance                              | 22/09/1999 | 05/10/1999 |                                  |                 |
| 1/0005  | 13_Batchsizeofactivesubstance                                                                | 28/07/1999 | n/a        |                                  |                 |
| X/0001  | X-3-ii_Addition of newstrength                                                               | 16/12/1998 | 29/03/1999 | SmPC, Annex II, Labelling and PL |                 |
| II/0002 | UpdateofSummaryofProductCharacteristicsand                                                   | 22/10/1998 | 01/02/1999 | SmPC and PL                      | Package Leaflet |